Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Change in Cash: 2010-2025

Historic Change in Cash for Altimmune (ALT) over the last 15 years, with Sep 2025 value amounting to -$121.9 million.

  • Altimmune's Change in Cash fell 375.07% to -$121.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.8 million, marking a year-over-year increase of 153.74%. This contributed to the annual value of -$98.2 million for FY2024, which is 508.67% down from last year.
  • Altimmune's Change in Cash amounted to -$121.9 million in Q3 2025, which was down 190.95% from $134.0 million recorded in Q2 2025.
  • Altimmune's 5-year Change in Cash high stood at $134.0 million for Q2 2025, and its period low was -$121.9 million during Q3 2025.
  • Moreover, its 3-year median value for Change in Cash was -$6.4 million (2023), whereas its average is -$4.5 million.
  • Its Change in Cash has fluctuated over the past 5 years, first spiked by 1,370.90% in 2021, then slumped by 1,202.89% in 2022.
  • Quarterly analysis of 5 years shows Altimmune's Change in Cash stood at $15.4 million in 2021, then crashed by 206.03% to -$16.4 million in 2022, then spiked by 394.86% to $48.3 million in 2023, then plummeted by 88.70% to $5.5 million in 2024, then plummeted by 375.07% to -$121.9 million in 2025.
  • Its Change in Cash was -$121.9 million in Q3 2025, compared to $134.0 million in Q2 2025 and $12.2 million in Q1 2025.